In the case of MDM2 inhibitors, the dose-limiting toxicities are hematological (neutropenia and thrombocytopenia [17,35], whereas for trametinib, the dose-limiting toxic effects include rash, diarrhea, and central serous retinopathy [36]. The gene discussed is MDM2; the disease is Thrombocytopenia.